Miles Wang, an OpenAI researcher, is leaving to launch a startup focused on developing AI models for drug discovery. He is in talks to raise $200 million at a $2 billion valuation, with Lightspeed potentially leading the funding round.
The new company may work on AI models to find new uses for existing drugs, which can result in faster time to revenue. Wang's experience at OpenAI includes co-authoring research papers on automating scientific discovery.
The funding discussions highlight investor interest in applying AI to life sciences, with other startups like Chai Discovery and Isomorphic Labs also raising significant funds for similar purposes.
